On October 18, 2025, Corbus Pharmaceuticals announced data from its Phase 1/2 clinical study of CRB-701, presented at ESMO25, showing efficacy in treating various tumors with 167 patients enrolled and notable response rates in head and neck cancer and cervical cancer.